If BPC-157 is stable, why store it cold?

The stability claim concerns enzymatic and acidic degradation. Chemical hydrolysis needs no enzyme and is what cold, dry storage addresses.

Does it need a reducing agent?

No. There is no cysteine in the sequence.

Shaking creates an air-liquid interface where peptides unfold and aggregate. Foam is the visible evidence.

BPC-157 Storage, Stability and Reconstitution

The short answer

BPC-157 is supplied lyophilised and is most stable dry, cold and dark. Its proline content confers enzymatic resistance and it lacks cysteine and methionine, so the common chemical degradation routes do not apply, leaving hydrolysis and physical handling as the practical concerns.

Key facts

Supplied as: White lyophilised powder
Enzymatic resistance: High (four prolines)
Disulfide risk: None (no cysteine)
Oxidation risk: Low (no methionine)
Main chemical route: Hydrolysis
Physical concern: Adsorption; freeze-thaw damage

Why the stability claim does not change storage

This is the point most likely to be got wrong. BPC-157 is described as stable in gastric juice, which is a claim about enzymatic and acidic resistance. Storage guidance addresses chemical hydrolysis, which proceeds without any enzyme and is a function of water, temperature and time. Proline protects against the first and does nothing about the second.

What the composition rules out

No cysteine, so no disulfide formation or scrambling and no reducing agent required. No methionine, so no thioether oxidation and no +16 Da satellite on a mass spectrum. Between them these account for most of what goes wrong with research peptides, and neither applies here.

Research material referenced

BPC-157 5mg, third-party HPLC tested

Buy BPC-157 · £15.99

What remains

Backbone hydrolysis, slowed but not prevented by proline. And an aspartate-glycine sequence at positions 11 to 13, which in some peptides is a site for aspartate-related rearrangement. This is useful to know, though it is a slower process than the routes that dominate elsewhere.

Reconstitution

Introduce diluent gently down the vial wall rather than onto the powder, and swirl rather than shake. Foaming indicates an air-liquid interface has formed, which is where peptides unfold before aggregating. BPC-157 is hydrophilic and dissolves readily, so vigorous agitation is never needed.

After reconstitution

Aliquot into single-use volumes. Each freeze-thaw cycle concentrates solutes at the advancing ice boundary and creates fresh interfaces, and neither is prevented by the peptide's enzymatic robustness. Chemical and physical stability are separate properties, and BPC-157 is strong on the first and ordinary on the second.

Signs of a problem

Cloudiness, particulates or discolouration in a reconstituted solution mean the material should not be relied on for a measurement. Difficulty dissolving at a concentration that previously worked suggests aggregation, which for a peptide this soluble would be a meaningful signal.

Frequently asked questions

If BPC-157 is stable, why store it cold?: The stability claim concerns enzymatic and acidic degradation. Chemical hydrolysis needs no enzyme and is what cold, dry storage addresses.
Does it need a reducing agent?: No. There is no cysteine in the sequence.
Why avoid shaking?: Shaking creates an air-liquid interface where peptides unfold and aggregate. Foam is the visible evidence.

Extended research context

The BPC-157 (Pentadecapeptide) deep dive

Deep dive: the pentadecapeptide sequence

BPC-157 is a synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is derived from a fragment identified in human gastric juice by the Zagreb research group (Sikirić and colleagues), whose body of published work spans three decades and covers models ranging from tendon repair to gut integrity. The 'BPC' initials stand for 'body protection compound', the group's original characterisation term.

Two forms: acetate salt vs arginate

BPC-157 is supplied most commonly as an acetate salt; a small subset of suppliers offer the arginate form, which has slightly different solubility and stability properties. For research reproducibility, keep the salt form consistent across a study and confirm which form the CoA specifies (mass ± counterion changes the reading).

Reading a BPC-157 CoA

A trustworthy BPC-157 CoA lists HPLC purity (target ≥98% area), mass-spec confirmation (~1,419 Da for the free peptide), water content (Karl Fischer), acetate content, and residual solvents. Some batches also include endotoxin data. Any missing category is a red flag for a compromised supply chain.

Research applications

▸Cell-culture models of gut epithelial integrity
▸Tendon fibroblast migration and collagen-synthesis assays
▸Angiogenesis models involving VEGF and NO signalling
▸Stability studies comparing acetate vs arginate salt forms
▸Analytical reference for pentadecapeptide HPLC methods

Handling checklist

✓Store lyophilised vial at −20 °C long-term (2–8 °C short-term)
✓Reconstitute with bacteriostatic water; a 5 mg vial dissolves cleanly
✓Aliquot reconstituted solution; keep refrigerated 2–8 °C, use within 28 days
✓Protect from light and repeated warming
✓Verify CoA: HPLC ≥98%, mass ~1,419 Da, salt form declared

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Mixing acetate and arginate BPC-157 across a study

Fix: Choose one salt form and stay with it. Different masses and solubility.

✗ Assuming stability at room temperature

Fix: Refrigerate reconstituted solution; discard after 28 days.

✗ Buying without a CoA

Fix: Only source from suppliers that publish batch HPLC + mass-spec data.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

The UK Peptides Editorial Team · Research library, UK Peptides

The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.

How we write and check this content Report a factual error in this article

More BPC-157 (Pentadecapeptide) articles

Popular across the research hub

One flagship guide from every other research category.

← Back to Forum